Age and Ageing 2004; 33: 143-149
© 2004, British Geriatrics Society
Research Paper |
Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? – The Calgary experience
Calgary Stroke Programme, Department of Clinical Neurosciences, University of Calgary and Foothills Hospital, Alberta, Canada
1 Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
2 Department of Elderly Medicine, Birmingham Heartlands Hospital, Birmingham, UK
3 Department of Community Health Sciences, University of Calgary, AB, Canada
4 Department of Medicine, University of Calgary, AB, Canada
Address correspondence to: J. E. Simon, Stroke Research Office, Room 1162, Foothills Medical Centre, 1403–29th St NW, Calgary, Alberta, Canada T2N 2T9. Fax: (+1) 403 944 1602. Email: jessica.simon{at}calgaryhealthregion.ca
Abstract
Background: acute ischaemic stroke is common in older people. There is one licensed acute treatment, intravenous recombinant tissue plasminogen activator, but little information is available on its safety in over 80 year olds.
Design: review of prospectively collected data on 62 consecutive patients, aged 80 years and over, treated with recombinant tissue plasminogen activator in a tertiary centre.
Methods: admission demographic data, clinical and CT stroke severity, symptomatic haemorrhage rate and other complications were compared between patients who were dead at 3 months and those who survived. Discharge location and functional scores outcome were reviewed. The results were compared to those of other studies.
Results: the in-hospital death rate was 24.2% and 3 month mortality 32.8%. Patients that died had higher stroke severity scores at presentation (NIHSS 20 versus 16, P = 0.04). Six patients (9.7%) suffered symptomatic intracranial haemorrhage (SICH), three were classified as fatal (4.8%). SICH was significantly associated with death by 3 months (P = 0.02). There were no other serious bleeding complications. The SICH rate is similar to that from other thrombolytic studies and the mortality rate is similar to the natural history of stroke in older populations.
Conclusion: older patients have high mortality and morbidity from stroke. Older patients should not be excluded from recombinant tissue plasminogen activator treatment on the basis of age alone.
Keywords: acute stroke, aged, 80 and over, thrombolytic therapy, elderly
Received March 5, 2003; Revision received . accepted in revised form .
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Summers, A. Leonard, D. Wentworth, J. L. Saver, J. Simpson, J. A. Spilker, N. Hock, E. Miller, P. H. Mitchell, and on behalf of the American Heart Association Counci Comprehensive Overview of Nursing and Interdisciplinary Care of the Acute Ischemic Stroke Patient: A Scientific Statement From the American Heart Association Stroke, August 1, 2009; 40(8): 2911 - 2944. [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Mateen, M. Nasser, B. R. Spencer, W. D. Freeman, A. Shuaib, B. M. Demaerschalk, and E. F. M. Wijdicks Outcomes of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Patients Aged 90 Years or Older Mayo Clin. Proc., April 1, 2009; 84(4): 334 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Meseguer, J. Labreuche, J. M. Olivot, H. Abboud, P. C. Lavallee, O. Simon, L. Cabrejo, A. Echeverria, I. F. Klein, M. Mazighi, et al. Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review Age Ageing, January 1, 2008; 37(1): 107 - 111. [Full Text] [PDF]
|
|
|
|
|
|
M. Uyttenboogaart, E. M. C. Schrijvers, P. C. Vroomen, J. De Keyser, and G.-J. Luijckx Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience Age Ageing, September 1, 2007; 36(5): 577 - 579. [Full Text] [PDF]
|
|
|
|
 |
|
 P A Ringleb, C. Schwark, M Kohrmann, S Kulkens, E Juttler, W Hacke, and P D Schellinger Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome J. Neurol. Neurosurg. Psychiatry, July 1, 2007; 78(7): 690 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Palumbo, J. M. Boulanger, M. D. Hill, D. Inzitari, A. M. Buchan, and on behalf of the CASES Investigators Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke Neurology, March 27, 2007; 68(13): 1020 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kim, G.A. Ford, C.S. Kidwell, S. Starkman, F. Vinuela, G.R. Duckwiler, R. Jahan, J.L. Saver, and for the UCLA Intra-Arterial Thrombolysis Investiga Intra-Arterial Thrombolysis for Acute Stroke in Patients 80 and Older: A Comparison of Results in Patients Younger than 80 Years AJNR Am. J. Neuroradiol., January 1, 2007; 28(1): 159 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Engelter, L. H. Bonati, and P. A. Lyrer Intravenous thrombolysis in stroke patients of >=80 versus <80 years of age--a systematic review across cohort studies. Age Ageing, November 1, 2006; 35(6): 572 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P N Sylaja, R. Cote, A. M Buchan, M. D Hill, and on behalf of Canadian Alteplase for Stroke Effecti Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study J. Neurol. Neurosurg. Psychiatry, July 1, 2006; 77(7): 826 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R J van Oostenbrugge, R M M Hupperts, and J Lodder Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 375 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Bateman, H. C. Schumacher, B. Boden-Albala, M. F. Berman, J.P. Mohr, R. L. Sacco, and J. Pile-Spellman Factors Associated With In-Hospital Mortality After Administration of Thrombolysis in Acute Ischemic Stroke Patients: An Analysis of the Nationwide Inpatient Sample 1999 to 2002 Stroke, February 1, 2006; 37(2): 440 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Hemphill III and P. Lyden Stroke thrombolysis in the elderly: Risk or benefit? Neurology, December 13, 2005; 65(11): 1690 - 1691. [Full Text] [PDF]
|
|
|
|
|
|
S. T. Engelter, M. Reichhart, L. Sekoranja, D. Georgiadis, A. Baumann, B. Weder, F. Muller, R. Luthy, M. Arnold, P. Michel, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis Neurology, December 13, 2005; 65(11): 1795 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Berrouschot, J. Rother, J. Glahn, T. Kucinski, J. Fiehler, and G. Thomalla Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old (>=80 Years) Stroke Patients Stroke, November 1, 2005; 36(11): 2421 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Hill, A. M. Buchan, and for The Canadian Alteplase for Stroke Effectivenes Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study Can. Med. Assoc. J., May 10, 2005; 172(10): 1307 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaste Thrombolysis: What More Does It Take? Stroke, February 1, 2005; 36(2): 200 - 202. [Full Text] [PDF]
|
|